Stockreport

ABIONYX Pharma Acknowledges the Clinical Results of the Phase 3 AEGIS-II Study Evaluating the Efficacy and Safety of CSL Behring's Human-plasma-derived apoA-I, CSL112 [Yahoo! Finance]

CSL LTD SP/ADR  (CSLLY) 
NASDAQ:AMEX Investor Relations: csl.com/investors
PDF ABIONYX Pharma (FR0012616852 – ABNX – PEA PME eligible) , a new generation biotech company dedicated to the discovery and development of innovative therapies based on t [Read more]